Insight into the Molecular Imaging of Alzheimer's Disease

International Journal of Biomedical Imaging

Volumn 2016, Issue , 2016, Pages

  Arora, Abishek ^a   Bhagat, Neeta ^a  

^a AMITY UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING SITES; BIOMARKERS; BRAIN; COMPUTERIZED TOMOGRAPHY; DIAGNOSIS; DISEASE CONTROL; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; METABOLISM; MOLECULAR IMAGING; NEURODEGENERATIVE DISEASES; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARTICLE BEAMS; POSITRON EMISSION TOMOGRAPHY; SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY;

ALZHEIMER'S DISEASE; CLINICAL ASSESSMENTS; DIAGNOSTIC ACCURACY; FUNCTIONAL MAGNETIC RESONANCE IMAGING; IMAGING BIOMARKERS; NEUROIMAGING TECHNIQUES; POSITRON EMISSION TOMOGRAPHY (PET); RECEPTOR BINDING SITE;

FUNCTIONAL NEUROIMAGING;

2 (4 AMINOPHENYL) 6 [2 (FLUOROETHOXY)]QUINOLINE F 18; 2 [1 [6 [2 FLUORANYLETHYL(METHYL)AMINO]NAPHTHALEN 2 YL]ETHYLIDENE]PROPANEDINITRILE F 18; 2 [2 (2 DIMETHYLAMINOTHIAZOL 5 YL)ETHENYL] 6 [2(FLUORO)ETHOXY]BENZOXAZOLE C 11; 2 [4 (2 FLUORANYLETHYL)PIPERIDIN 1 YL]PYRIMIDO[1,2 A]BENZIMIDAZOLE F 18; 2 [4 (METHYLAMINO)PHENYL] 1,3 BENZOTHIAZOL 6 OL C 11; 2 [6 (METHYLAMINO)PHENYL] 1,3 BENZOTHIAZOL 6 OL C 11; 4 N METHYLAMINO 4 HYDROXYSTILBENE C 11; 6 [(3 FLUORO 2 HYDROXY)PROPOXY] 2 (4 DIMETHYLAMINOPHENYL)QUINOLINE F 18; 6 [(3 FLUORO 2 HYDROXY)PROPOXY] 2 (4 METHYLAMINOPHENYL)QUINOLINE F 18; AMYLOID; ARACHIDONIC ACID C 11; BIOLOGICAL MARKER; FLORBETABEN; FLORBETAPIR F 18; FLORTAUCIPIR F 18; FLUTAFURANOL F 18; FLUTEMETAMOL F 18; IODO N BUTAN 2 YL 1 (2 CHLOROPHENYL) N METHYLISOQUINOLINE 3 CARBOXAMIDE I 123; N METHYL 4,4 DIAMINOSTILBENE C 11; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE C 11; TRACER; UNCLASSIFIED DRUG; VERAPAMIL C 11; [4 [6 (METHYLAMINO)PYRIDIN 3 YL]BUTA 1,3 DIENYL]BENZO[D]THIAZOL 6 OL C 11;

ALZHEIMER DISEASE; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DISEASE MARKER; HUMAN; MOLECULAR IMAGING; NERVOUS SYSTEM INFLAMMATION; NEUROIMAGING; NONHUMAN; PATHOPHYSIOLOGY; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SPECT SCANNER;

EID: 84962683154     PISSN: 16874188     EISSN: 16874196     Source Type: Journal    
DOI: 10.1155/2016/7462014     Document Type: Review

References (177)

1. D. P. Chapman, S. M. Williams, T. W. Strine, R. F. A. M. J. Moore, "Dementia and its implications for public health, " Preventing Chronic Disease, vol. 3, no. 2, article A34, 2006.
2. D. C. Mash, D. D. Flynn, L. T. Potter, "Loss ofM2muscarine receptors in the cerebral cortex in Alzheimer's disease and experimental cholinergic denervation, " Science, vol. 228, no. 4703, pp. 1115-1117, 1985.
3. J. D. Gazewood, D. R. Richards, K. Clebak, "Parkinson disease: an update, " American Family Physician, vol. 87, no. 4, pp. 267-273, 2013.
4. J. Massano, "Cognitive impairment and dementia-an update, " Frontiers in Neurology, vol. 3, article 153, 2012.
5. V. Kljajevic, "Overestimating the effects of healthy aging, " Frontiers in Aging Neuroscience, vol. 7, article 164, 2015.
6. B. Frost and M. I. Diamond, "Prion-like mechanisms in neurodegenerative diseases, " Nature Reviews Neuroscience, vol. 11, no. 3, pp. 155-159, 2010.
7. F. M. M. Lu and Z. Yuan, "PET/SPECT molecular imaging in clinical neuroscience: recent advances in the investigation of CNS diseases, " Quantitative Imaging in Medicine and Surgery, vol. 5, no. 3, pp. 433-447, 2015.
8. J. F. Jiménez Bonilla and J. M. Carril Carril, "Molecular neuroimaging in degenerative dementias, " Revista Espanola de Medicina Nuclear e Imagen Molecular, vol. 32, no. 5, pp. 301-309, 2013.
9. P. A. Apurva, P. M. Bipin, P. M. Kirti, "Role of PET scan in clinical practice, " Gujarat Medical Journal, vol. 68, no. 2, pp. 19-22, 2013.
10. R. Weissleder and U. Mahmood, "Molecular imaging, " Radiology, vol. 219, no. 2, pp. 316-333, 2001.
11. E. Kim, O. D. Howes, S. Kapur, "Molecular imaging as a guide for the treatment of central nervous system disorders, " Dialogues in Clinical Neuroscience, vol. 15, no. 3, pp. 315-328, 2013.
12. S. P. Mueller, J. F. Polak, M. F. Kijewski, B. L. Holman, "Collimator selection for SPECT brain imaging: the advantage of high resolution, " Journal of Nuclear Medicine, vol. 27, no. 11, pp. 1729-1738, 1986.
13. L. Jiang, Y. Tu, H. Shi, Z. Cheng, "PET probes beyond 18FFDG, " Journal of Biomedical Research, vol. 28, no. 6, pp. 435-446, 2014.
14. W. Mier and D. Mier, "Advantages in functional imaging of the brain, " Frontiers in Human Neuroscience, vol. 9, p. 249, 2015.
15. T. Varghese, R. Sheelakumari, J. S. James, P. S. Mathuranath, "A review of neuroimaging biomarkers of Alzheimer's disease, " Neurology Asia, vol. 18, no. 3, pp. 239-248, 2013.
16. K. Blennow, M. J. de Leon, H. Zetterberg, "Alzheimer's disease, " The Lancet, vol. 368, no. 9533, pp. 387-403, 2006.
17. Alzheimer's Association, "2010 Alzheimer's disease facts and figures, " Alzheimer's and Dementia, vol. 6, no. 2, pp. 158-194, 2010.
18. W. T. Hu, A. Chen-Plotkin, S. E. Arnold et al., "Novel CSF biomarkers for Alzheimer's disease and mild cognitive impairment, " Acta Neuropathologica, vol. 119, no. 6, pp. 669-678, 2010.
19. L. Devi and H. K. Anandatheerthavarada, "Mitochondrial trafficking of APP and alpha synuclein: relevance to mitochondrial dysfunction in Alzheimer's and Parkinson's diseases, " Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, vol. 1802, no. 1, pp. 11-19, 2010.
20. C. Mancuso, G. Scapagnini, D. Currò et al., "Mitochondrial dysfunction, free radical generation and cellular stress response in neurodegenerative disorders, " Frontiers in Bioscience, vol. 12, no. 3, pp. 1107-1123, 2007.
21. H. W. Querfurth and F. M. LaFerla, "Alzheimer's disease, " The New England Journal of Medicine, vol. 362, no. 4, pp. 329-344, 2010.
22. P. Davidsson, A. Westman-Brinkmalm, C. L. Nilsson et al., "Proteome analysis of cerebrospinal fluid proteins in Alzheimer patients, " NeuroReport, vol. 13, no. 5, pp. 611-615, 2002.
23. M. A. Korolainen, T. A. Nyman, P. Nyyssönen, E. S. Hartikainen, T. Pirttilä, "Multiplexed proteomic analysis of oxidation and concentrations of cerebrospinal fluid proteins in Alzheimer disease, " Clinical Chemistry, vol. 53, no. 4, pp. 657-665, 2007.
24. H. Zetterberg, U. Ruëtschi, E. Portelius et al., "Clinical proteomics in neurodegenerative disorders, " Acta Neurologica Scandinavica, vol. 118, no. 1, pp. 1-11, 2008.
25. C. Sihlbom, P. Davidsson, M. Sjögren, L.-O. Wahlund, C. L. Nilsson, "Structural and quantitative comparison of cerebrospinal fluid glycoproteins inAlzheimer's disease patients and healthy individuals, " Neurochemical Research, vol. 33, no. 7, pp. 1332-1340, 2008.
26. M. Puchades, S. F. Hansson, C. L. Nilsson, N., reasen, K. Blennow, P. Davidsson, "Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease, " Molecular Brain Research, vol. 118, no. 1-2, pp. 140-146, 2003.
27. C. Hesse, C. L. Nilsson, K. Blennow, P. Davidsson, "Identification of the apolipoprotein E4 isoform in cerebrospinal fluid with preparative two-dimensional electrophoresis and matrix assisted laser desorption/ionization-time of flight-mass spectrometry, " Electrophoresis, vol. 22, no. 9, pp. 1834-1837, 2001.
28. E. Tarkowski, K. Blennow, A. Wallin, A. Tarkowski, "Intracerebral production of tumor necrosis factor-, a local neuroprotective agent, in Alzheimer disease and vascular dementia, " Journal of Clinical Immunology, vol. 19, no. 4, pp. 223-230, 1999.
29. I. Blasko, W. Lederer, H. Oberbauer et al., "Measurement of thirteen biological markers in CSF of patients with Alzheimer's disease and other dementias, " Dementia and Geriatric Cognitive Disorders, vol. 21, no. 1, pp. 9-15, 2005.
30. D. Galimberti, N. Schoonenboom, P. Scheltens et al., "Intrathecal chemokine synthesis in mild cognitive impairment and Alzheimer disease, " Archives of Neurology, vol. 63, no. 4, pp. 538-543, 2006.
31. E. Gómez-Tortosa, I. Gonzalo, S. Fanjul et al., "Cerebrospinal fluid markers in dementia with Lewy bodies compared with Alzheimer disease, " Archives of Neurology, vol. 60, no. 9, pp. 1218-1222, 2003.
32. E. Rota, G. Bellone, P. Rocca, B. Bergamasco, G. Emanuelli, P. Ferrero, "Increased intrathecal TGF-1, but not IL-12, IFN-and IL-10 levels in Alzheimer's disease patients, " Neurological Sciences, vol. 27, no. 1, pp. 33-39, 2006.
33. R. M. Evans, S. Hui, A. Perkins, D. K. Lahiri, J. Poirier, M. R. Farlow, "Cholesterol and APOE genotype interact to influence Alzheimer disease progression, " Neurology, vol. 62, no. 10, pp. 1869-1871, 2004.
34. M.-K. K. Sun, J. Hongpaisan, D. L. Alkon, "Postischemic PKC activation rescues retrograde and anterograde long-term memory, " Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 34, pp. 14676-14680, 2009.
35. J. de Barry, C. M. Liégeois, A. Janoshazi, "Protein kinaseCas a peripheral biomarker for Alzheimer's disease, " Experimental Gerontology, vol. 45, no. 1, pp. 64-69, 2010.
36. T. Isagawa, H. Mukai, K. Oishi et al., "Dual effects of PKN and protein kinase C on phosphorylation of tau protein by glycogen synthase kinase-3, " Biochemical and Biophysical Research Communications, vol. 273, no. 1, pp. 209-212, 2000.
37. H. Zetterberg, K. Blennow, E. Hanse, "Amyloid and APP as biomarkers for Alzheimer's disease, " Experimental Gerontology, vol. 45, no. 1, pp. 23-29, 2010.
38. H. Zetterberg, U., reasson, O. Hansson et al., "Elevated cerebrospinal fluid BACE1 activity in incipient alzheimer disease, " Archives of Neurology, vol. 65, no. 8, pp. 1102-1107, 2008.
39. J. A. Hardy and G. A. Higgins, "Alzheimer's disease: the amyloid cascade hypothesis, " Science, vol. 256, no. 5054, pp. 184-185, 1992.
40. T. L. Spires-Jones, W. H. Stoothoff, A. de Calignon, P. B. Jones, B. T. Hyman, "Tau pathophysiology in neurodegeneration: a tangled issue, " Trends in Neurosciences, vol. 32, no. 3, pp. 150-159, 2009.
41. M. A. Korolainen, T. A. Nyman, T. Aittokallio, T. Pirttilä, "An update on clinical proteomics in Alzheimer's research, " Journal of Neurochemistry, vol. 112, no. 6, pp. 1386-1414, 2010.
42. S. Davinelli, M. Intrieri, C. Russo et al., "The "Alzheimer's disease signature': potential perspectives for novel biomarkers, " Immunity and Ageing, vol. 8, article 7, 2011.
43. S. Dassati, A. Waldner, R. Schweigreiter, "Apolipoprotein D takes center stage in the stress response of the aging and degenerative brain, " Neurobiology of Aging, vol. 35, no. 7, pp. 1632-1642, 2014.
44. S. Lorente-Cebrián, A. G. G. Costa, S. Navas-Carretero et al., "An update on the role of omega-3 fatty acids on inflammatory and degenerative diseases, " Journal of Physiology and Biochemistry, vol. 71, no. 2, pp. 341-349, 2015.
45. X. Li, K. S. Montine, C. D. Keene, T. J. Montine, "Different mechanisms of apolipoprotein E isoform-dependent modulation of prostaglandin E2 production and triggering receptor expressed on myeloid cells 2 (TREM2) expression after innate immune activation of microglia, " The FASEB Journal, vol. 29, no. 5, pp. 1754-1762, 2015.
46. L. K. Ferreira and G. F. Busatto, "Neuroimaging in Alzheimer's disease: current role in clinical practice and potential future applications, " Clinics, vol. 66, supplement 1, pp. 19-24, 2011.
47. R. C. Barber, "Biomarkers for early detection of Alzheimer disease, " Journal of the American Osteopathic Association, vol. 110, no. 9, pp. S10-S15, 2010.
48. L. Zhang, R. C.-C. Chang, L.-W. W. Chu, H. K.-F. Mak, "Current neuroimaging techniques in Alzheimer's disease and applications in animal models, " American Journal of Nuclear Medicine andMolecular Imaging, vol. 2, no. 3, pp. 386-404, 2012.
49. K. J. Anstey, R. Eramudugolla, D. E. Hosking, N. T. Lautenschlager, R. A. Dixon, "Bridging the translation gap: from dementia risk assessment to advice on risk reduction, " Journal of Prevention of Alzheimer's Disease, vol. 2, no. 3, pp. 189-198, 2015.
50. T. L. Spires-Jones and B. Hyman, "The intersection of amyloid and tau at synapses in Alzheimer's disease, " Neuron, vol. 82, no. 4, pp. 756-771, 2014.
51. M. Tabaton, X. Zhu, G. Perry, M. A. Smith, L. Giliberto, "Signaling effect of amyloid-42 on the processing of APP, " Experimental Neurology, vol. 221, no. 1, pp. 18-25, 2010.
52. W. Qin, L. Ho, J. Wang, E. Peskind, G. M. Pasinetti, "S100A7, a novel Alzheimer's disease biomarker with non-amyloidogenic-secretase activity acts via selective promotion of ADAM-10, " PLoS ONE, vol. 4, no. 1, Article ID e4183, 2009.
53. P. L. Ross, Y. N. Huang, J. N. Marchese et al., "Multiplexed protein quantitation in Saccharomyces cerevisiae using aminereactive isobaric tagging reagents, " Molecular and Cellular Proteomics, vol. 3, no. 12, pp. 1154-1169, 2004.
54. A. Thompson, J. Schäfer, K. Kuhn et al., "Tandem mass tags: a novel quantification strategy for comparative analysis of complex protein mixtures by MS/MS, " Analytical Chemistry, vol. 75, no. 8, pp. 1895-1904, 2003.
55. S. P. Gygi, B. Rist, S. A. Gerber, F. Turecek, M. H. Gelb, R. Aebersold, "Quantitative analysis of complex protein mixtures using isotope-coded affinity tags, " Nature Biotechnology, vol. 17, no. 10, pp. 994-999, 1999.
56. A. Schmidt, J. Kellermann, F. Lottspeich, "A novel strategy for quantitative proteomics using isotope-coded protein labels, " Proteomics, vol. 5, no. 1, pp. 4-15, 2005.
57. C. Tian, D. Liu, W. Xiang et al., "Analyses of the similarity and difference of global gene expression profiles in cortex regions of three neurodegenerative diseases: sporadic Creutzfeldt-Jakob disease (sCJD), fatal familial insomnia (FFI), Alzheimer's disease (AD), " Molecular Neurobiology, vol. 50, no. 2, pp. 473-481, 2014.
58. G. M. McKhann, D. S. Knopman, H. Chertkow et al., "The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease, " Alzheimer's & Dementia, vol. 7, no. 3, pp. 263-269, 2011.
59. M. Benadiba, G. Luurtsema, L. Wichert-Ana, C. A. Buchpigel, G. B. Filho, "New molecular targets for PET and SPECT imaging in neurodegenerative diseases, " Revista Brasileira de Psiquiatria, vol. 34, no. 2, pp. S125-S148, 2012.
60. H. Shim, M. J. Ly, S. K. Tighe, "Brain imaging in the differential diagnosis of young-onset dementias, " Psychiatric Clinics of North America, vol. 38, no. 2, pp. 281-294, 2015.
61. M. E. Phelps, "Positron emission tomography providesmolecular imaging of biological processes, " Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 16, pp. 9226-9233, 2000.
62. R. Dann, D. Christman, J. Fowler, B. MacGregor, A. Wolf, "Metabolic mapping of functional activity in human subjects with the [18F] fluorodeoxyglucose technique, " Science, vol. 212, no. 4495, pp. 678-680, 1981.
63. K. Strijckmans, "The isochronous cyclotron: principles and recent developments, " Computerized Medical Imaging and Graphics, vol. 25, no. 2, pp. 69-78, 2001.
64. C. Halldin, B. Gulyás, O. Langer, L. Farde, "Brain radioligands-state of the art and new trends, " Quarterly Journal of Nuclear Medicine, vol. 45, no. 2, pp. 139-152, 2001.
65. D. W. Townsend, "Dual-modality imaging: combining anatomy and function, " Journal of Nuclear Medicine, vol. 49, no. 6, pp. 938-955, 2008.
66. J. M. Kofler, D. D. Cody, R. L. Morin, "CT protocol review and optimization, " Journal of the American College of Radiology, vol. 11, no. 3, pp. 267-270, 2014.
67. M. Laruelle, M. Slifstein, Y. Huang, "Positron emission tomography: imaging and quantification of neurotransporter availability, " Methods, vol. 27, no. 3, pp. 287-299, 2002.
68. A. Baert, Encyclopedia of Diagnostic Imaging, Springer, Berlin, Germany, 2008.
69. I. Buvat, S. Laffont, J. Le Cloirec, P. Bourguet, R. Di Paola, "Importance of the choice of the collimator for the detection of small lesions in scintimammography: a phantomstudy, " Physics in Medicine and Biology, vol. 46, no. 5, pp. 1343-1355, 2001.
70. B. Palumbo, T. Buresta, S. Nuvoli et al., "SPECT and PET serve as molecular imaging techniques and in Vivo biomarkers for brain metastases, " International Journal of Molecular Sciences, vol. 15, no. 6, pp. 9878-9893, 2014.
71. S. L. Pimlott and A. Sutherland, "Molecular tracers for the PET and SPECT imaging of disease, " Chemical Society Reviews, vol. 40, no. 1, pp. 149-162, 2011.
72. V. L. Villemagne, M. T. Fodero-Tavoletti, K. E. Pike, R. Cappai, C. L. Masters, C. C. Rowe, "The ART of loss: a imaging in the evaluation of Alzheimer's disease and other dementias, " Molecular Neurobiology, vol. 38, no. 1, pp. 1-15, 2008.
73. M. Laruelle, M. Slifstein, Y. Huang, "Relationships between radiotracer properties and image quality in molecular imaging of the brain with positron emission tomography, " Molecular Imaging & Biology, vol. 5, no. 6, pp. 363-375, 2003.
74. V. W. Pike, "PET radiotracers: crossing the blood-brain barrier and survivingmetabolism, " Trends in Pharmacological Sciences, vol. 30, no. 8, pp. 431-440, 2009.
75. W. M. Pardridge, "Drug and gene delivery to the brain: the vascular route, " Neuron, vol. 36, no. 4, pp. 555-558, 2002.
76. J. E. Maggio, E. R. Stimson, J. R. Ghilardi et al., "Reversible in vitro growth ofAlzheimer disease-amyloid plaques by deposition of labeled amyloid peptide, " Proceedings of the National Academy of Sciences of the United States of America, vol. 89, no. 12, pp. 5462-5466, 1992.
77. R. P. Friedland, R. E. Majocha, J. M. Reno, L. R. Lyle, C. A. Marotta, "Development of an anti-A monoclonal antibody for in vivo imaging of amyloid angiopathy in Alzheimer's disease, " Molecular Neurobiology, vol. 9, no. 1-3, pp. 107-113, 1994.
78. H. J. Lee, Y. Zhang, C. Zhu, K. Duff, W. M. Pardridge, "Imaging brain amyloid of Alzheimer disease in vivo in transgenic micewith anAbeta peptide radiopharmaceutical, " Journal of Cerebral Blood Flow Metabolism, vol. 22, no. 2, pp. 223-231, 2002.
79. C. A. Mathis, Y. Wang, D. P. Holt, G.-F. F. Huang, M. L. Debnath, W. E. Klunk, "Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents, " Journal of Medicinal Chemistry, vol. 46, no. 13, pp. 2740-2754, 2003.
80. Z.-P. P. Zhuang, M.-P. P. Kung, A. Wilson et al., "Structureactivity relationship of imidazo [1, 2-a]pyridines as ligands for detecting-amyloid plaques in the brain, " Journal of Medicinal Chemistry, vol. 46, no. 2, pp. 237-243, 2003.
81. H. Engler, A. F. Santillo, S. X. Wang et al., "In vivo amyloid imaging with PET in frontotemporal dementia, " European Journal of Nuclear Medicine and Molecular Imaging, vol. 35, no. 1, pp. 100-106, 2008.
82. G. D. Rabinovici, H. J. Rosen, A. Alkalay et al., "Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD, " Neurology, vol. 77, no. 23, pp. 2034-2042, 2011.
83. V. L. Villemagne, K. Ong, R. S. Mulligan et al., "Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias, " Journal of NuclearMedicine, vol. 52, no. 8, pp. 1210-1217, 2011.
84. W. E. Klunk, H. Engler, A. Nordberg et al., "Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B, " Annals of Neurology, vol. 55, no. 3, pp. 306-319, 2004.
85. B. J. Bacskai, G. A. Hickey, J. Skoch et al., "Four-dimensional multiphoton imaging of brain entry, amyloid binding, clearance of an amyloid-ligand in transgenic mice, " Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 21, pp. 12462-12467, 2003.
86. C. C. Rowe, S. Ng, U. Ackermann et al., "Imaging-amyloid burden in aging and dementia, " Neurology, vol. 68, no. 20, pp. 1718-1725, 2007.
87. C. C. Rowe, K. A. Ellis, M. Rimajova et al., "Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging, " Neurobiology of Aging, vol. 31, no. 8, pp. 1275-1283, 2010.
88. A. Forsberg, H. Engler, O. Almkvist et al., "PET imaging of amyloid deposition in patients with mild cognitive impairment, " Neurobiology of Aging, vol. 29, no. 10, pp. 1456-1465, 2008.
89. P. Edison, C. C. Rowe, J. O. Rinne et al., "Amyloid load inParkinson's disease dementia and Lewy body dementiameasured with [11C]PIB positron emission tomography, " Journal of Neurology, Neurosurgery and Psychiatry, vol. 79, no. 12, pp. 1331-1338, 2008.
90. M. A. Mintun, G. N. Larossa, Y. I. Sheline et al., " [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease, " Neurology, vol. 67, no. 3, pp. 446-452, 2006.
91. N. S. Mason, C. A. Mathis, W. E. Klunk, "Positron emission tomography radioligands for in vivo imaging of A plaques, " Journal of Labelled Compounds and Radiopharmaceuticals, vol. 56, no. 3-4, pp. 89-95, 2013.
92. A. E. Johnson, F. Jeppsson, J. Sandell et al., "AZD2184: a radioligand for sensitive detection of-amyloid deposits, " Journal of Neurochemistry, vol. 108, no. 5, pp. 1177-1186, 2009.
93. S. Nyberg, M. E. Jönhagen, Z. Cselényi et al., "Detection of amyloid in Alzheimer's disease with positron emission tomography using [11C]AZD2184, " European Journal of Nuclear Medicine and Molecular Imaging, vol. 36, no. 11, pp. 1859-1863, 2009.
94. A. Nordberg, "PET imaging of amyloid in Alzheimer's disease, " The Lancet Neurology, vol. 3, no. 9, pp. 519-527, 2004.
95. K. Shoghi-Jadid, G. W. Small, E. D. Agdeppa et al., "Localization of neurofibrillary tangles and-amyloid plaques in the brains of living patients with alzheimer disease, " The American Journal of Geriatric Psychiatry, vol. 10, no. 1, pp. 24-35, 2002.
96. P. W. Thompson, L. Ye, J. L. Morgenstern et al., "Interaction of the amyloid imaging tracer FDDNP with hallmark Alzheimer's disease pathologies, " Journal of Neurochemistry, vol. 109, no. 2, pp. 623-630, 2009.
97. E. D. Agdeppa, V. Kepe, K. Shoghi-Jadid et al., "In vivo and in vitro labeling of plaques and tangles in the brain of an Alzheimer's disease patient: a case study, " Journal of Nuclear Medicine, vol. 42, no. 5, p. 65, 2001.
98. L. M. Smid, V. Kepe, H. V. Vinters et al., "Postmortem 3-D brain hemisphere cortical tau and amyloid-pathology mapping and quantification as a validation method of neuropathology imaging, " Journal of Alzheimer's Disease, vol. 36, no. 2, pp. 261-274, 2013.
99. G. W. Small, E. D. Agdeppa, V. Kepe, N. Satyamurthy, S.-C. Huang, J. R. Barrio, "In vivo brain imaging of tangle burden in humans, " Journal ofMolecular Neuroscience, vol. 19, no. 3, pp. 321-327, 2002.
100. H. Barthel and O. Sabri, "Florbetaben to trace amyloid-in the Alzheimer brain by means of PET, " Journal of Alzheimer's Disease, vol. 26, no. 3, pp. 117-121, 2011.
101. S. R. Choi, G. Golding, Z. Zhuang et al., "Preclinical properties of 18F-AV-45: a PET agent for Abeta plaques in the brain, " Journal of Nuclear Medicine, vol. 50, no. 11, pp. 1887-1894, 2009.
102. D. F. Wong, P. B. Rosenberg, Y. Zhou et al., "In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (flobetapir F 18), " Journal of NuclearMedicine, vol. 51, no. 6, pp. 913-920, 2010.
103. C. M. Clark, J. A. Schneider, B. J. Bedell et al., "Useofflorbetapir-PET for imaging-amyloid pathology, " Journal of the American Medical Association, vol. 305, no. 3, pp. 275-283, 2011.
104. C. C. Rowe, U. Ackerman, W. Browne et al., "Imagingof amyloid in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism, " The Lancet Neurology, vol. 7, no. 2, pp. 129-135, 2008.
105. S. Shokouhi, D. Claassen, W. Riddle, "Imaging brain metabolism and pathology in Alzheimer's disease with positron emission tomography, " Journal of Alzheimer's Disease & Parkinsonism, vol. 4, no. 2, article 143, 2014.
106. N. Nelissen, K. Van Laere, L. Thurfjell et al., "Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease, " Journal of Nuclear Medicine, vol. 50, no. 8, pp. 1251-1259, 2009.
107. R. Vandenberghe, K. Adamczuk, P. Dupont, K. V. Laere, G. Chételat, "Amyloid PET in clinical practice: its place in the multidimensional space of Alzheimer's disease, " NeuroImage: Clinical, vol. 2, no. 1, pp. 497-511, 2013.
108. C. C. Rowe and V. L. Villemagne, "Brain amyloid imaging, " Journal of Nuclear Medicine, vol. 52, no. 11, pp. 1733-1740, 2011.
109. Z. Cselényi, M. E. Jönhagen, A. Forsberg et al., "Clinical validation of 18F-AZD4694, an amyloid-specific PET radioligand, " Journal of Nuclear Medicine, vol. 53, no. 3, pp. 415-424, 2012.
110. A. Jureús, B.-M. M. Swahn, J. Sandell et al., "Characterization of AZD4694, a novel fluorinated A plaque neuroimaging PET radioligand, " Journal of Neurochemistry, vol. 114, no. 3, pp. 784-794, 2010.
111. Y. Kudo, N. Okamura, S. Furumoto et al., "2-(2-[2-Dimethylaminothiazol-5-yl]ethenyl)-6-(2-[fluoro]ethoxy)benzoxazole: a novel PET agent for in vivo detection of dense amyloid plaques in Alzheimer's disease patients, " Journal of Nuclear Medicine, vol. 48, no. 4, pp. 553-561, 2007.
112. Y. Kudo, "Development of amyloid imaging PET probes for an early diagnosis of Alzheimer's disease, " Minimally Invasive TherapyandAlliedTechnologies, vol. 15, no. 4, pp. 209-213, 2006.
113. M. Ono, A. Wilson, J. Nobrega et al., "11C-labeled stilbene derivatives as A-aggregate-specific PET imaging agents for Alzheimer's disease, " Nuclear Medicine and Biology, vol. 30, no. 6, pp. 565-571, 2003.
114. W. E. Klunk, H. Engler, A. Nordberg et al., "Imaging the pathology of Alzheimer's disease: amyloid-imaging with positron emission tomography, " Neuroimaging Clinics of North America, vol. 13, no. 4, pp. 781-789, 2003.
115. N. P. L. G. Verhoeff, A. A. Wilson, S. Takeshita et al., "In-vivo imaging of Alzheimer disease-amyloid with [11C]SB-13 PET, " American Journal of Geriatric Psychiatry, vol. 12, no. 6, pp. 584-595, 2004.
116. M. C. Hong, Y. K. Kim, J. Y. Choi et al., "Synthesis andevaluation of stilbene derivatives as a potential imaging agent of amyloid plaques, " Bioorganic andMedicinal Chemistry, vol. 18, no. 22, pp. 7724-7730, 2010.
117. K. R. Eun and X. Chen, "Development of Alzheimer's disease imaging agents for clinical studies, " Frontiers in Bioscience, vol. 13, no. 2, pp. 777-789, 2008.
118. C. Wu, V. W. Pike, Y. Wang, "Amyloid imaging: from benchtop to bedside, " Current Topics in Developmental Biology, vol. 70, pp. 171-213, 2005.
119. M.-P. Kung, C. Hou, Z.-P. Zhuang, D. Skovronsky, H. F. Kung, "Binding of two potential imaging agents targeting amyloid plaques in postmortem brain tissues of patients with Alzheimer's disease, " Brain Research, vol. 1025, no. 1-2, pp. 98-105, 2004.
120. F. Hernández and J. Avila, "Tauopathies, " Cellular andMolecular Life Sciences, vol. 64, no. 17, pp. 2219-2233, 2007.
121. K. Arima, "Ultrastructural characteristics of tau filaments in tauopathies: immuno-electron microscopic demonstration of tau filaments in tauopathies, " Neuropathology, vol. 26, no. 5, pp. 475-483, 2006.
122. P. J. Muchowski, "Protein misfolding, amyloid formation, neurodegeneration: a critical role for molecular chaperones" Neuron, vol. 35, no. 1, pp. 9-12, 2002.
123. M. G. Spillantini andM. Goedert, "Tau pathology and neurodegeneration, " The Lancet Neurology, vol. 12, no. 6, pp. 609-622, 2013.
124. N. S. Honson, R. L. Johnson, W. Huang, J. Inglese, C. P. Austin, J. Kuret, "Differentiating Alzheimer disease-associated aggregates with small molecules, " Neurobiology of Disease, vol. 28, no. 3, pp. 251-260, 2007.
125. K. N. Schafer, S. Kim, A. Matzavinos, J. Kuret, "Selectivity requirements for diagnostic imaging of neurofibrillary lesions in Alzheimer's disease: a simulation study, " NeuroImage, vol. 60, no. 3, pp. 1724-1733, 2012.
126. A. Taghavi, S. Nasir, M. Pickhardt et al., "N-benzylidenebenzohydrazides as novel and selective tau-PHF ligands, " Journal of Alzheimer's Disease, vol. 27, no. 4, pp. 835-843, 2011.
127. S. J. Kemp, L. J. Storey, J. Storey, J. Rickard, "Ligands for aggregated tau molecules, " US Patent, 2014.
128. V. L. Villemagne and N. Okamura, "In vivo tau imaging: obstacles and progress, " Alzheimer's & Dementia, vol. 10, no. 3, supplement, pp. S254-S264, 2014.
129. M. T. Fodero-Tavoletti, N. Okamura, S. Furumoto et al., " 18FTHK523: a novel in vivo tau imaging ligand for Alzheimer's disease, " Brain, vol. 134, part 4, pp. 1089-1100, 2011.
130. R. Harada, N. Okamura, S. Furumoto, T. Tago et al., "Comparison of the binding characteristics of [18F] THK-523 and other amyloid imaging tracers to Alzheimer's disease pathology, " European Journal of Nuclear Medicine and Molecular Imaging, vol. 40, no. 1, pp. 125-132, 2013.
131. V. L. Villemagne, S. Furumoto, M. T. Fodero-Tavoletti et al., "In vivo evaluation of a novel tau imaging tracer for Alzheimer's disease, " European Journal of Nuclear Medicine and Molecular Imaging, vol. 41, no. 5, pp. 816-826, 2014.
132. M. T. Fodero-Tavoletti, S. Furumoto, L. Taylor et al., "Assessing THK523 selectivity for tau deposits in Alzheimer's disease and non Alzheimer's disease tauopathies, " Acta Veterinaria Scandinavica, vol. 6, article 11, 2014.
133. N. Okamura, S. Furumoto, R. Harada et al., "Novel 18Flabeled arylquinoline derivatives for noninvasive imaging of tau pathology in Alzheimer disease, " Journal of Nuclear Medicine, vol. 54, no. 8, pp. 1420-1427, 2013.
134. E. R. Zimmer, A. Leuzy, S. Gauthier, P. Rosa-Neto, "Developments in tau PET imaging, " The Canadian Journal of Neurological Sciences, vol. 41, no. 05, pp. 547-553, 2014.
135. N. Okamura, S. Furumoto, M. T. Fodero-Tavoletti et al., "Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using 18F-THK5105 PET, " Brain, vol. 137, no. 6, pp. 1762-1771, 2014.
136. Y. Li, W. Tsui, H. Rusinek et al., "Cortical laminar binding of PET amyloid and tau tracers in Alzheimer disease, " Journal of Nuclear Medicine, vol. 56, no. 2, pp. 270-273, 2015.
137. W. Zhang, J. Arteaga, D. K. Cashion et al., "A highly selective and specific PET tracer for imaging of tau pathologies, " Journal of Alzheimer's Disease, vol. 31, no. 3, pp. 601-612, 2012.
138. S. Förster, T. Grimmer, I. Miederer et al., "Regional expansion of hypometabolism in Alzheimer's disease follows amyloid deposition with temporal delay, " Biological Psychiatry, vol. 71, no. 9, pp. 792-797, 2012.
139. D. T. Chien, S. Bahri, A. K. Szardenings et al., "Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807, " Journal of Alzheimer'sDisease, vol. 34, no. 2, pp. 457-468, 2013.
140. M. Mintun, A. Schwarz, A. Joshi et al., "Exploratory analyses of regional human brain distribution of the PET tau tracer F18-labeled T807 (AV-1541) in subjects with normal cognitive function or cognitive impairment thought to be due to Alzheimer's disease, " Alzheimer's & Dementia, vol. 9, no. 4, p. P842, 2013.
141. D. T. Chien, A. K. Szardenings, S. Bahri et al., "Early clinical PET imaging results with the novel PHF-tau radioligand [F18]-T808, " Journal of Alzheimer's Disease, vol. 38, no. 1, pp. 171-184, 2014.
142. M. Maruyama, H. Shimada, T. Suhara et al., "Imaging of tau pathology in a tauopathy mouse model and in alzheimer patients compared to normal controls, " Neuron, vol. 79, no. 6, pp. 1094-1108, 2013.
143. G. W. Small, V. Kepe, L. M. Ercoli et al., "PET of brain amyloid and tau in mild cognitive impairment, " The New England Journal of Medicine, vol. 355, no. 25, pp. 2652-2663, 2006.
144. J. Stefaniak and J. O'Brien, "Imaging of neuroinflammation in dementia: a review, " Journal of Neurology, Neurosurgery & Psychiatry, vol. 87, pp. 21-28, 2016.
145. V. Pizza, A. Agresta, C. W. D'Acunto, M. Festa, A. Capasso, "Neuroinflammation and ageing: current theories and an overview of the data, " Reviews on Recent Clinical Trials, vol. 6, no. 3, pp. 189-203, 2011.
146. R. M. Ransohoff and J. El Khoury, "Microglia in health and disease, " Cold Spring Harbor Perspectives in Biology, 2015.
147. D. G. Walker and L. F. F. Lue, "Immune phenotypes of microglia in human neurodegenerative disease: challenges to detecting microglial polarization in human brains, " Alzheimer's Research &Therapy, vol. 7, no. 1, p. 56, 2015.
148. Z. Su, F. Roncaroli, P. F. Durrenberger et al., "The 18-kDa mitochondrial translocator protein in human gliomas: an 11C-(R)PK11195 PET imaging and neuropathology study, " Journal of Nuclear Medicine, vol. 56, no. 4, pp. 512-517, 2015.
149. P. Gut, M. Zweckstetter, R. B. Banati, "Lost in translocation: the functions of the 18-kD translocator protein, " Trends in Endocrinology & Metabolism, vol. 26, no. 7, pp. 349-356, 2015.
150. M.-K. K. Chen and T. R. R. Guilarte, "Translocator protein 18 kDa (TSPO): molecular sensor of brain injury and repair, " Pharmacology andTherapeutics, vol. 118, no. 1, pp. 1-17, 2008.
151. A. Cagnin, D. J. Brooks, A. M. Kennedy et al., "In-vivo measurement of activated microglia in dementia, " The Lancet, vol. 358, no. 9280, pp. 461-467, 2001.
152. S. Chalon, C. Pellevoisin, S. Bodard, M.-P. Vilar, J.-C. Besnard, D. Guilloteau, "Iodinated PK 11195 as an ex vivo marker of neuronal injury in the lesioned rat brain, " Synapse, vol. 24, no. 4, pp. 334-339, 1996.
153. J. J. Versijpt, F. Dumont, K. J. Van Laere et al., "Assessment of neuroinflammation and microglial activation in Alzheimer's disease with radiolabelled PK11195 and single photon emission computed tomography: a pilot study, " European Neurology, vol. 50, no. 1, pp. 39-47, 2003.
154. S. Venneti, C. A. Wiley, J. Kofler, "Imaging microglial activation during neuroinflammation and Alzheimer's disease, " Journal of Neuroimmune Pharmacology, vol. 4, no. 2, pp. 227-243 2009.
155. A. S. C. Ching, B. Kuhnast, A. Damont, D. Roeda, B. Tavitian, F. Dollé, "Current paradigm of the 18-kDa translocator protein (TSPO) as a molecular target for PET imaging in neuroinflammation and neurodegenerative diseases, " Insights into Imaging, vol. 3, no. 1, pp. 111-119, 2012.
156. H. Boutin, F. Chauveau, C. Thominiaux et al., "11C-DPA-713: a novel peripheral benzodiazepine receptor PET ligand for in vivo imaging of neuroinflammation, " Journal of Nuclear Medicine, vol. 48, no. 4, pp. 573-581, 2007.
157. H. Boutin, C. Prenant, R. Maroy et al., " [18F]DPA-714: direct comparison with [11C]PK11195 in a model of cerebral ischemia in rats, " PLoS ONE, vol. 8, no. 2, Article ID e56441, 2013.
158. N. Van Camp, R. Boisgard, B. Kuhnast et al., "In vivo imaging of neuroinflammation: a comparative study between [18F]PBR111, [11C]CLINME and [11C]PK11195 in an acute rodent model, " European Journal of Nuclear Medicine and Molecular Imaging, vol. 37, no. 5, pp. 962-972, 2010.
159. G. Abourbeh, B. Thézé, R. Maroy et al., "Imaging microglial/macrophage activation in spinal cords of experimental autoimmune encephalomyelitis rats by positron emission tomography using the mitochondrial 18 kDa translocator protein radioligand [18F]DPA-714, " The Journal of Neuroscience, vol. 32, no. 17, pp. 5728-5736, 2012.
160. D. Tang, M. R. Hight, E. T. McKinley et al., "Quantitative preclinical imaging of TSPO expression in glioma using N, Ndiethyl-2-(2-(4-(2-18F-fluoroethoxy) phenyl)-5, 7-dimethylpyrazolo [ 1, 5-A]pyrimidin-3-yl)acetamide, " Journal of Nuclear Medicine, vol. 53, no. 2, pp. 287-294, 2012.
161. N. Arlicot, A. Katsifis, L. Garreau et al., "Evaluation of CLINDE as potent translocator protein (18 kDa) SPECT radiotracer reflecting the degree of neuroinflammation in a rat model of microglial activation, " European Journal of Nuclear Medicine and Molecular Imaging, vol. 35, no. 12, pp. 2203-2211, 2008.
162. F. Mattner, D. L. Bandin, M. Staykova et al., "Evaluation of [123]-CLINDE as a potent SPECT radiotracer to assess the degree of astroglia activation in cuprizone-induced neuroinflammation, " European Journal of Nuclear Medicine and Molecular Imaging, vol. 38, no. 8, pp. 1516-1528, 2011.
163. I. López-González, E. Aso, M. Carmona et al., "Neuroinflammatory gene regulation, mitochondrial function, oxidative stress, brain lipid modifications with disease progression in tau P301S transgenic mice as a model of frontotemporal lobar degeneration-tau, " Journal of Neuropathology & Experimental Neurology, vol. 74, no. 10, pp. 975-999, 2015.
164. J. A. Garcá-Sevilla, P. V. Escribá, J. Guimón, "Imidazoline receptors and human brain disorders, " Annals of the New York Academy of Sciences, vol. 881, pp. 392-409, 1999.
165. S. F. Carter, M. Schöll, O. Almkvist et al., "Evidence for astrocytosis in prodromal Alzheimer disease provided by 11Cdeuterium-L-deprenyl: a multitracer PET paradigm combining 11C-Pittsburgh compound B and 18F-FDG, " Journal of Nuclear Medicine, vol. 53, no. 1, pp. 37-46, 2012.
166. A. F. Santillo, J. P. Gambini, L. Lannfelt et al., "In vivo imaging of astrocytosis in Alzheimer's disease: an 11C-L-deuteriodeprenyl and PIB PET study, " European Journal of Nuclear Medicine and Molecular Imaging, vol. 38, no. 12, pp. 2202-2208, 2011.
167. K. Kawamura, Y. Kimura, J. Yui et al., "PET study using [11C]FTIMD with ultra-high specific activity to evaluate I2-imidazoline receptors binding in rat brains, " Nuclear Medicine and Biology, vol. 39, no. 2, pp. 199-206, 2012.
168. M. Wang, L. Xu, M. Gao, K. D. Miller, G. W. Sledge, Q. H. H. Zheng, " [11C]enzastaurin, the first design and radiosynthesis of a new potential PET agent for imaging of protein kinase C, " Bioorganic & Medicinal Chemistry Letters, vol. 21, no. 6, pp. 1649-1653, 2011.
169. M.-K. K. Sun and D. L. Alkon, "The 'memory kinases': roles of PKC isoforms in signal processing and memory formation, " Progress inMolecular Biology and Translational Science, vol. 122, pp. 31-59, 2014.
170. C. Wu, C. Wang, D. C. Popescu et al., "A novel PET marker for in vivo quantification of myelination, " Bioorganic & Medicinal Chemistry, vol. 18, no. 24, pp. 8592-8599, 2010.
171. M. Doubrovin, J. T. Che, I. Serganova et al., "Monitoring the induction of heat shock factor 1/heat shock protein 70 expression following 17-allylamino-demethoxygeldanamycin treatment by positron emission tomography and optical reporter gene imaging, "Molecular Imaging, vol. 11, no. 1, pp. 67-76, 2012.
172. C. Chiu, M. C. Miller, R. Monahan, D. P. Osgood, E. G. Stopa, G. D. Silverberg, "P-glycoprotein expression and amyloid accumulation in human aging and Alzheimer's disease: preliminary observations, " Neurobiology of Aging, vol. 36, no. 9, pp. 2475-2482, 2015.
173. G. Luurtsema, J. Verbeek, M. Lubberink et al., "Carbon-11 labeled tracers for in vivo imaging P-glycoprotein function: kinetics, advantages and disadvantages, " Current Topics in Medicinal Chemistry, vol. 10, no. 17, pp. 1820-1833, 2010.
174. G. Esposito, G. Giovacchini, J.-S. S. Liow et al., "Imaging neuroinflammation in Alzheimer's disease with radiolabeled arachidonic acid and PET, " Journal of NuclearMedicine, vol. 49, no. 9, pp. 1414-1421, 2008.
175. M. Singh, "Essential fatty acids, DHA and human brain, " Indian Journal of Pediatrics, vol. 72, no. 3, pp. 239-242, 2005.
176. S. I. Rapoport, E. Ramadan, M. Basselin, "Docosahexaenoic acid (DHA) incorporation into the brain from plasma, as an in vivo biomarker of brain DHA metabolism and neurotransmission, " Prostaglandins& Other Lipid Mediators, vol. 96, no. 1-4, pp. 109-113, 2011.
177. J. A. Conquer, M. C. Tierney, J. Zecevic, W. J. Bettger, R. H. Fisher, "Fatty acid analysis of blood plasma of patients with Alzheimer's disease, other types of dementia, cognitive impairment, " Lipids, vol. 35, no. 12, pp. 1305-1312, 2000.